These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Recommendations for laboratory standardization of next generation sequencing in hematological malignancies]. Xu CS; Li XQ; Liu HX; Li CB; Chen Z; Cai JP; Peng MT Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(41):3204-3208. PubMed ID: 31694113 [TBL] [Abstract][Full Text] [Related]
3. Biological markers in haematological malignancies. Lemal R; Tournilhac O; Bay JO Bull Cancer; 2014 Jun; 101 Suppl 1():S7-11. PubMed ID: 24966076 [TBL] [Abstract][Full Text] [Related]
4. [Identification by epigenome analysis of novel molecular targets for therapy in hematopoietic malignancies]. Nojima M Rinsho Ketsueki; 2011 Mar; 52(3):111-7. PubMed ID: 21471697 [No Abstract] [Full Text] [Related]
5. [Front line of molecular-targeted therapy for hematological malignancies]. Kizaki M Rinsho Byori; 2013 Mar; 61(3):283-90. PubMed ID: 23785799 [TBL] [Abstract][Full Text] [Related]
6. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics. McCarron SL; Haslam K; Crampe M; Langabeer SE Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862 [No Abstract] [Full Text] [Related]
7. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Shigdar S; Ward AC; De A; Yang CJ; Wei M; Duan W Br J Haematol; 2011 Oct; 155(1):3-13. PubMed ID: 21810089 [TBL] [Abstract][Full Text] [Related]
8. Special report: multiple molecular testing of cancers to identify targeted therapies. BlueCross BlueShield Association Technol Eval Cent Assess Program Exec Summ; 2013 Jun; 28(1):1-2. PubMed ID: 23865106 [No Abstract] [Full Text] [Related]
9. MicroRNA expression profiling in bone marrow: implications in hematological malignancies. Costa A; Osório C; Dias S Biotechnol J; 2009 Jan; 4(1):88-97. PubMed ID: 19156746 [TBL] [Abstract][Full Text] [Related]
10. Identifying cancer mutations as therapeutic targets. Azvolinsky A J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25122735 [No Abstract] [Full Text] [Related]
11. Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. Li S; Jaye DL; Bradley KT; Zhang L; Saxe D; Deeb G; Hill CE; Mann KP Arch Pathol Lab Med; 2017 Mar; 141(3):341-354. PubMed ID: 28055240 [TBL] [Abstract][Full Text] [Related]
12. Current status of molecular targeted therapy for hematologic malignancies: introduction. Ueda T Int J Clin Oncol; 2014 Feb; 19(1):1-2. PubMed ID: 24357412 [No Abstract] [Full Text] [Related]
13. [Hematologic malignancies/pediatric malignancy]. Usui N Gan To Kagaku Ryoho; 2013 May; 40(5):582. PubMed ID: 23957064 [No Abstract] [Full Text] [Related]
14. [Proteomics techniques and their application in haemato-oncologic malignancies]. Zelená J; Hájek R Cas Lek Cesk; 2007; 146(7):586-92. PubMed ID: 17722845 [TBL] [Abstract][Full Text] [Related]
15. DNA methyltransferases in hematologic malignancies. Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483 [TBL] [Abstract][Full Text] [Related]
16. Cytogenetics in solid tumors: lessons from the Philadelphia Chromosome. Sudoyo AW; Hardi F Acta Med Indones; 2011 Jan; 43(1):68-73. PubMed ID: 21339549 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders. Bench AJ; Erber WN; Scott MA Clin Lab Haematol; 2005 Jun; 27(3):148-71. PubMed ID: 15938721 [TBL] [Abstract][Full Text] [Related]
19. Introduction to a cancer symposium for the practitioner. Tefferi A; Rajkumar SV; Adjei AA Mayo Clin Proc; 2005 Aug; 80(8):1085-6. PubMed ID: 16092590 [No Abstract] [Full Text] [Related]